Get the Stockscreener App
7.99
4.31%
-0.36
Regenxbio Inc stock is traded at $7.99, with a volume of 1.09M.
It is down -4.31% in the last 24 hours and down -46.91% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$8.35
Open:
$8.35
24h Volume:
1.09M
Relative Volume:
1.31
Market Cap:
$404.48M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-1.519
EPS:
-5.26
Net Cash Flow:
$-194.72M
1W Performance:
-22.65%
1M Performance:
-46.91%
6M Performance:
-10.53%
1Y Performance:
+9.15%
1-Day Range:
$7.94
$8.63
1-Week Range:
$7.94
$10.62
52-Week Range:
$5.035
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.99 | 422.70M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-07-25 | Resumed | Raymond James | Outperform |
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
REGENXBIO Faces Class Action Lawsuit - Intellectia AI
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of REGENXBIO Inc. Securities and Sets a Lead Plaintiff Deadline of April 14, 2026 - GlobeNewswire Inc.
Weekly Buzz:FDA Okays NVCR's Cancer Device; RGNX Gets CRL;ONCO To Buy XBOT; PHIO's PH-762 Sets Pace - RTTNews
Rx Rundown: Eli Lilly, Supreme Group, Regenxbio and more - Medical Marketing and Media
REGENXBIO: Cautiously Bullish After FDA Setbacks (NASDAQ:RGNX) - Seeking Alpha
Can REGENXBIO Inc. be recession proofSell Signal & Consistent Profit Trading Strategies - mfd.ru
Why did RGNX shares plummet 19% after-hours today? - MSN
Regenxbio stock drops on FDA setback for RGX-121 gene therapy - MSN
2026-02-12 | REGENXBIO Inc. (RGNX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:RGNX | Press Release - Stockhouse
What is HC Wainwright's Estimate for REGENXBIO Q3 Earnings? - MarketBeat
Regenxbio highlights 56 percent women workforce on International Day of Women and Girls in Science - Traders Union
US FDA’s Rare Pediatric Disease Flexibility Rhetoric Undermined By Regenxbio’s CRL - Citeline News & Insights
Regenxbio stock price target lowered to $32 at H.C. Wainwright after FDA rejection - Investing.com Nigeria
Regenxbio (RGNX) Analyst Rating Update: Price Target Lowered by HC Wainwright | RGNX Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages REGENXBIO Inc. (RGNX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
FDA rejects RegenxBio's gene therapy for rare disease, a major setback for Rockville company - The Business Journals
FDA Delivers Regenxbio Another Blow, This Time for RGX-121 - Citeline News & Insights
Gap Down: What’s the beta of REGENXBIO Inc. stock2025 Key Lessons & Expert-Curated Trade Recommendations - baoquankhu1.vn
Goldman Sachs Lowers Price Target for RGNX, Keeps Neutral Rating - GuruFocus
FDA rejects Regenxbio treatment in another blow to gene therapy - BioPharma Dive
REGENXBIO (NASDAQ:RGNX) Price Target Lowered to $18.00 at Morgan Stanley - MarketBeat
Morgan Stanley Lowers Price Target for RGNX to $18 | RGNX Stock News - GuruFocus
Chardan Capital Lowers Price Target for (RGNX) but Maintains 'Bu - GuruFocus
The Analyst Verdict: Regenxbio In The Eyes Of 5 Experts - Benzinga
Why Is REGENXBIO Stock Falling Today?Regenxbio (NASDAQ:RGNX) - Benzinga
Chardan Capital Lowers REGENXBIO (NASDAQ:RGNX) Price Target to $50.00 - MarketBeat
Regenxbio stock price target lowered by Goldman Sachs on RGX-121 setback - Investing.com
Regenxbio Shares Fall After FDA Declines Approval of Hunter Syndrome Treatment - marketscreener.com
Regenxbio Stock Pre-Market (-18%): FDA Rejects Key Drug RGX-121 - Trefis
REGENXBIO Faces FDA Setback on RGX-121 Gene Therapy - TipRanks
Regenxbio (RGNX) Shares Dip 15% Following FDA Setback - GuruFocus
Dismay as FDA blocks Regenxbio's Hunter syndrome therapy - pharmaphorum
FDA Denies Regenxbio Gene Therapy in Latest Rare Disease Setback - Bloomberg.com
Regenxbio stock drops on FDA setback for RGX-121 gene therapy (RGNX:NASDAQ) - Seeking Alpha
Regenxbio drops after FDA rejects gene therapy for rare disease - TradingView
REGENXBIO Inc. (NASDAQ:RGNX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
US FDA declines to approve Regenxbio’s gene therapy for rare disease - 93.3 The Drive
Regenxbio's RGX-121 Faces FDA Approval Setback - Intellectia AI
Regenxbio Stock Still Has Over 300% Upside Despite FDA Pushback On Hunter Syndrome Drug: Clear Street - Stocktwits
Why Did RGNX Shares Plummet 19% After-Hours Today? - Asianet Newsable
Bronstein, Gewirtz & Grossman, LLC Encourages REGENXBIO Inc. (RGNX) Investors to Inquire about Securities Investigation - ACCESS Newswire
FDA Slams REGENXBIO's MPS II Gene Therapy RGX-121 With CRL - CGTLive®
US FDA declines to approve Regenxbio’s rare disease drug - KFGO
Regenxbio's MPS II Gene Therapy RGX-121 Hit With CRL - NeurologyLive
Regenxbio's Gene Therapy for Hunter Syndrome Fails to Win FDA Approval - marketscreener.com
Regenxbio (RGNX) Shares Drop 21% Following FDA Setback - GuruFocus
Regenxbio falls after FDA rejects rare disease therapy - TradingView
Regenxbio (RGNX) Faces FDA Setback for Hunter Syndrome Treatment - GuruFocus
REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II - TradingView
After-hours movers: ON Semiconductor, Credo, Upwork, Regenxbio, and more - Investing.com
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regenxbio Inc Stock (RGNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Simpson Curran | Chief Executive Officer |
Oct 09 '25 |
Sale |
12.62 |
20,811 |
262,635 |
216,162 |
1.12%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):